Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + exemestane versus placebo + exemestane in postmenopausal women with ER-positive advanced breast cancer refractory to letrozole or anastrozole
2008-008698-69Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + exemestane with Placebo + exemestane (2 arms). Primary endpoint: Progression-free survival. Started May 2009; status: completed.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-008698-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008698-69.